(Press-News.org) The study, carried out by scientists from Navarrabiomed, the Institute of Neurosciences CSIC-UMH, and IRB Barcelona, has been published in Nature Metabolism.
In 2022, 7,500 new cases of melanoma—the most aggressive type of skin cancer—were diagnosed in Spain.
A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d’Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.
The journal Nature Metabolism has published the results of the study, which offers an alternative therapeutic approach to treat melanoma, the most deadly type of skin cancer, which affects 16.3 women and 14.6 men per 100,000 inhabitants in Spain.
The development of future clinical trials to validate and confirm the action of ranolazine in cancer patients will be facilitated by the fact that it has already been approved for use in humans and is being administered in clinical practice to treat chronic angina.
Details about the study
In most cases, patients with melanoma respond well to therapies directed against one of the key genes in tumour progression, namely BRAF. However, they soon develop resistance to these therapies and the tumours grow back. In addition, the latest clinical studies suggest that these patients show a poorer response to immunotherapy.
This study has provided a deeper understanding of the role of fatty acid metabolism in the development of resistance to BRAF inhibitors and demonstrated the capacity of ranolazine to slow down tumour progression. More importantly, this drug increases the visibility of melanoma cells to the immune system, thereby improving response to immunotherapies and increasing the ability of lymphocytes to control tumour growth.
Multicentre study
The research has been coordinated from Navarrabiomed by Dr. Imanol Arozarena Martinicorena, head of the Cancer Signaling Unit, and is part of the doctoral thesis by Marta Redondo Muñoz (Public University of Navarre), a researcher in the same unit.
The work has been carried out in close collaboration with the Institute of Neurosciences, involving Dr. Francisco Javier Rodríguez-Baena, under the direction of Dr. Berta Sánchez Laorden, principal investigator of the Cellular Plasticity in Development and Disease group, and with IRB Barcelona, where the ICREA researcher Dr. Salvador Aznar Benitah leads the Stem Cells and Cancer lab, as well as the translational laboratory Systemic Metabolic Alterations in Cancer.
Navarrabiomed has designed and managed the development of the project, and also carried out experiments related to resistance to targeted therapies and the study of how ranolazine affects the immunogenicity of melanoma cells. “This study demonstrates that it is possible to pharmacologically reorganise the metabolism of the tumour cell to improve the effect of targeted therapies and immunotherapies. The next challenge is to demonstrate the clinical effect of these combinations in patients and study the potential of ranolazine in other types of cancer. To do this, we need to better understand how this drug acts both in tumour cells and in the immune system, says Dr. Imanol Arozarena.
The Institute of Neurosciences (a joint centre of the CSIC and the Miguel Hernández University), conducted the immunotherapy trials with mice and the study of immune cells in the tumour microenvironment. “Immunotherapy has established itself as a fundamental therapeutic strategy for melanoma and other types of cancer. Despite this, many patients do not respond optimally to these treatments. This work shows the beneficial impact of the combination of ranolazine with immunotherapy in preclinical models of melanoma, thus supporting its possible application in patients, highlights Dr. Berta Sánchez-Laorden.
Scientists at IRB Barcelona performed single-cell RNA sequencing analyses, which have revealed in detail the effect of ranolazine on the metabolic state of tumour cells. “We suspected that fatty acid metabolism was crucial in the most aggressive forms of melanoma, but being able to confirm this with a drug already approved for use in humans is highly relevant. Hopefully, these results can pave the way to change clinical practice, says Dr. Aznar Benitah.
Incidence
In 2022, 7,500 new cases of skin melanoma were diagnosed in Spain. Worldwide, this type of cancer accounts for 3.4% of the total number of cancer cases detected. Despite accounting for only 10% of skin cancer cases, melanoma is responsible for 90% of deaths associated with skin tumours.
Thanks to the development of targeted therapies and immunotherapies, the clinical treatment of individuals with melanoma has improved, but 50% of patients are still unresponsive and/or acquire resistance to these therapies. The combination of current therapies with ranolazine would offer a therapeutic alternative for these patients, improving their clinical response.
The study has been funded through institutional support and resources granted by various organisations: the Ministry of Science and Innovation, the Carlos III Health Institute, the Government of Navarre, the Spanish Multidisciplinary Melanoma Group (GEM), and the Melanoma Research Alliance.
Dr. Aznar Benitah's laboratory is supported by the European Research Council (ERC) within the framework of the Horizon 2020 research and innovation programme of the European Union, the Government of Catalonia, the Spanish Ministry of Science and Innovation, the La Marató de TV3 Foundation, the Lilliane Bettencourt Foundation, the Spanish Association Against Cancer, and the Worldwide Cancer Research Fund (WCRF).
END
A medication used for heart conditions improves the efficacy of current treatments for melanoma in mouse models
2023-08-10
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Effectiveness of video gameplay restrictions questioned in new study
2023-08-10
Legal restrictions placed on the amount of time young people in China can play video games may be less effective than originally thought, a new study has revealed.
To investigate the effectiveness of the policy, a team of researchers led by the University of York, analysed over 7 billion hours of playtime data from tens of thousands of games, with data drawn from over two billion accounts from players in China, where legal restrictions on playtime for young people have been in place since 2019.
The research team, however, did not find evidence of a decrease in heavy play of games after these ...
A new mechanism encouraging the brain to self-repair after an ischemic stroke
2023-08-10
Researchers from Tokyo Medical and Dental University (TMDU) identify lipids stimulating self-repair mechanisms in the brain after ischemic stroke
Tokyo, Japan – Patients often experience functional decline after an ischemic stroke, especially due to the brain’s resistance to regenerate after damage. Yet, there is still potential for recovery as surviving neurons can activate repair mechanisms to limit and even reverse the damage caused by the stroke. How is it triggered though?
In a study published ...
Researchers find new pathway for HIV invasion of cell nucleus
2023-08-10
The researchers also identified three proteins that are needed for the virus to carry out the invasion and have in turn synthesized molecules (potential drugs) that can target one of the proteins, potentially leading to new treatments for AIDS.
“We have revealed a protein pathway that appears to have a direct impact on diseases, which opens up a new area for potential drug development,” says the study’s senior author Aurelio Lorico, MD PhD, Professor of Pathology and interim Chief Research Officer at Touro University Nevada College of Osteopathic Medicine.
HIV infection requires the virus to enter a cell and gain access to the well-guarded nucleus in order ...
MSK Research Highlights, August 10, 2023
2023-08-10
New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — a hub for basic science and translational research within MSK — found a potential target against neuroendocrine transformation in lung and prostate cancers; discovered new clues about why donor T cells attack certain tissues in graft-versus-host disease; shed light on why T cells let go of their prey; and used CRISPR interference and dynamic cell-state transitions to discover enhancers that affect early human development.
Targeting exportin 1 may help prevent neuroendocrine transformation in lung and prostate cancers
Over time, some lung and prostate ...
Johns Hopkins researchers develop gut-restricted drug to treat IBD
2023-08-10
A new study of mice and lab-grown human colon “organoids” indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.
The experimental drug, given orally, inhibits a gut enzyme that is overproduced in people and in animal models of IBD, a disorder estimated by the U.S. Centers for Disease Control and Prevention to afflict more than 3 million adult Americans.
A report on the new study was published Aug. 9 in Science Translational Medicine.
IBD, a disease category that includes Crohn’s ...
Course correction keeps Parker Solar Probe on track for Venus flyby
2023-08-10
NASA’s Parker Solar Probe executed a short maneuver on Aug. 3, 2023, that kept the spacecraft on track to hit the aim point for the mission’s sixth Venus flyby on Monday, Aug. 21, 2023.
Operating on preprogrammed commands from mission control at the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland, Parker fired its small thrusters for 4.5 seconds, enough to adjust its trajectory by 77 miles and speed up – by 1.4 seconds – its closest approach to Venus. The precise timing and position are critical to that flyby, the sixth of seven approaches in which Parker uses the planet’s gravity to tighten ...
Computer-aided cell analysis for faster diagnosis of blood diseases
2023-08-10
Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.
Blood disorders are often characterized by altered numbers and aberrant shapes of red and white blood cells. To diagnose the diseases, physicians classically examine blood smears on a slide under a microscope. This type of diagnosis is straightforward, but evaluation by experienced experts is difficult because the changes are sometimes ...
National QIS Research Centers to host virtual career fair
2023-08-10
UPTON, NY– Registration is now open for the third Quantum Information Science Career Fair hosted by the U.S. Department of Energy (DOE) Office of Science’s National Quantum Information Science (QIS) Research Centers. The virtual event takes place on Wednesday, Sept. 13.
The event aims to make undergraduates, graduate students, postdocs and early-career professionals aware of the wide range of QIS careers they can pursue—including technical and scientific roles as well as positions that facilitate research and bring awareness to the field, such as ...
Enhanced gut microbiome diversity linked to improved survival in children receiving stem cell transplants
2023-08-10
(WASHINGTON, August 10, 2023) – Researchers in Italy have shown for the first time that among children who have undergone a donor stem cell transplant, the presence of diverse species of micro-organisms in the intestinal tract before the transplant resulted in significantly better overall patient survival and fewer complications. The study, published today in the journal Blood, adds to a growing body of research unraveling the role gut health plays in health outcomes.
“Our study provides the first evidence of a relationship between pre-transplant microbial diversity in the intestinal tract and post-transplant ...
SwRI micropatch algorithm improves ground-to-spacecraft software update efficiency
2023-08-10
San Antonio – August 10, 2023 – Southwest Research Institute developed an algorithm to remotely update and repair spacecraft software using less time and data than conventional techniques.
The tool not only improves the overall efficiency of satellite software transmissions but also can recover data from failed over-the-air updates and malicious cyberattacks. It works by identifying missing bytes and other errors before deploying a custom “micropatch” to the damaged or missing software.
“Instead of updating an entire file or operating system, which is typically required with over-the-air satellite software updates, our ...